“Toci": Two arthritis drugs that previously failed in treating Covid-19 — Roche Holding AG’s tocilizumab and Sanofi-Regeneron Pharmaceuticals Inc.’s sarilumab — are now showing a meaningful effect in helping reduce the burden of disease in some patients.
It seems that when the drugs are used is key. The latest data comes from a trial involving patients who were treated within 24 hours of needing hospital care in an intensive care unit.